Cargando…
Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: A retrospective cohort study
Paclitaxel is a commonly used chemotherapeutic agent. To minimize the risk of hypersensitivity reactions (HSRs), which occur in approximately 16–42% of patients, premedication with dexamethasone, clemastine, and ranitidine was standard of care. As of October 2019, ranitidine is no longer available....
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271659/ https://www.ncbi.nlm.nih.gov/pubmed/35811355 http://dx.doi.org/10.1002/prp2.985 |